EP4232045A4 - Compositions de berbérine ursodésoxycholate et méthodes associées pour le traitement de stéatose hépatique, de diabète et d'hyperlipidémie - Google Patents

Compositions de berbérine ursodésoxycholate et méthodes associées pour le traitement de stéatose hépatique, de diabète et d'hyperlipidémie

Info

Publication number
EP4232045A4
EP4232045A4 EP21882127.0A EP21882127A EP4232045A4 EP 4232045 A4 EP4232045 A4 EP 4232045A4 EP 21882127 A EP21882127 A EP 21882127A EP 4232045 A4 EP4232045 A4 EP 4232045A4
Authority
EP
European Patent Office
Prior art keywords
hyperlipidemia
diabetes
compositions
methods
liver disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21882127.0A
Other languages
German (de)
English (en)
Other versions
EP4232045A1 (fr
Inventor
Liping Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Hightide Biopharmaceutical Ltd
Original Assignee
Shenzhen Hightide Biopharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Hightide Biopharmaceutical Ltd filed Critical Shenzhen Hightide Biopharmaceutical Ltd
Publication of EP4232045A1 publication Critical patent/EP4232045A1/fr
Publication of EP4232045A4 publication Critical patent/EP4232045A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21882127.0A 2020-10-23 2021-10-22 Compositions de berbérine ursodésoxycholate et méthodes associées pour le traitement de stéatose hépatique, de diabète et d'hyperlipidémie Pending EP4232045A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063104754P 2020-10-23 2020-10-23
PCT/CN2021/125490 WO2022083713A1 (fr) 2020-10-23 2021-10-22 Compositions de berbérine ursodésoxycholate et méthodes associées pour le traitement de stéatose hépatique, de diabète et d'hyperlipidémie

Publications (2)

Publication Number Publication Date
EP4232045A1 EP4232045A1 (fr) 2023-08-30
EP4232045A4 true EP4232045A4 (fr) 2024-09-04

Family

ID=81289703

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21882127.0A Pending EP4232045A4 (fr) 2020-10-23 2021-10-22 Compositions de berbérine ursodésoxycholate et méthodes associées pour le traitement de stéatose hépatique, de diabète et d'hyperlipidémie

Country Status (3)

Country Link
EP (1) EP4232045A4 (fr)
CN (1) CN116782898A (fr)
WO (1) WO2022083713A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023088463A1 (fr) * 2021-11-22 2023-05-25 Shenzhen Hightide Biopharmaceutical Ltd. Compositions et procédés de berbérine ursodésoxycholate pour modulation de compositions du microbiome intestinal
WO2024120452A1 (fr) * 2022-12-07 2024-06-13 Shenzhen Hightide Biopharmaceutical Ltd. Compositions et méthodes de prophylaxie et de traitement de la covid-19
WO2024169937A1 (fr) * 2023-02-15 2024-08-22 Shenzhen Hightide Biopharmaceutical Ltd. Compositions de tauroursodésoxycholate de berbérine et procédés associés
WO2024179570A1 (fr) * 2023-03-01 2024-09-06 Shenzhen Hightide Biopharmaceutical Ltd. Compositions et méthodes de traitement de l'hypertriglycéridémie

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011420A1 (fr) * 2007-07-18 2009-01-22 Mitsubishi Tanabe Pharma Corporation Agent thérapeutique pour le diabète de type 2
WO2010106420A1 (fr) * 2009-03-17 2010-09-23 Axcan Pharma, Inc. Procédé de traitement d'une stéatohépatite non alcoolique au moyen de doses élevées d'acide ursodésoxycholique
WO2016015634A1 (fr) * 2014-07-29 2016-02-04 Shenzhen Hightide Biopharmaceutical, Ltd. Sels de berbérine, sels ursodésoxycholiques et des combinaisons, des procédés de préparation et d'application correspondants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108864077B (zh) * 2017-05-12 2020-05-22 深圳君圣泰生物技术有限公司 小檗碱有机酸盐的固体形式及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011420A1 (fr) * 2007-07-18 2009-01-22 Mitsubishi Tanabe Pharma Corporation Agent thérapeutique pour le diabète de type 2
WO2010106420A1 (fr) * 2009-03-17 2010-09-23 Axcan Pharma, Inc. Procédé de traitement d'une stéatohépatite non alcoolique au moyen de doses élevées d'acide ursodésoxycholique
WO2016015634A1 (fr) * 2014-07-29 2016-02-04 Shenzhen Hightide Biopharmaceutical, Ltd. Sels de berbérine, sels ursodésoxycholiques et des combinaisons, des procédés de préparation et d'application correspondants

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LI ZHAO ET AL: "Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease", BMC ENDOCRINE DISORDERS, BIOMED CENTRAL LTD, LONDON, UK, vol. 17, no. 1, 28 February 2017 (2017-02-28), pages 1 - 8, XP021242660, DOI: 10.1186/S12902-017-0165-7 *
LIU L ET AL: "HTD1801 a novel treatment addressing the underlying metabolic features of NAFLD/NASH", HEPATOLOGY V70 SUPPL.1 2019 20191001 JOHN WILEY AND SONS INC. NLD, vol. 70, no. Supplement 1, 1 October 2019 (2019-10-01), XP009555841, ISSN: 1527-3350 *
LIU, LP; BAI, R; YU, L; YU, M; FU, XX: "HTD1801 A NOVEL TREATMENT FOR NAFLD/NASH AND PRIMARY SCLEROSING CHOLANGITIS (PSC)", HEPATOLOGY, vol. 70, no. Suppl 1, 1 October 2019 (2019-10-01), pages 1261A - 1262A, XP009555813 *
See also references of WO2022083713A1 *
XING LIAN-JUN ET AL: "Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 668, no. 3, 1 October 2011 (2011-10-01), NL, pages 467 - 471, XP093189113, ISSN: 0014-2999, DOI: 10.1016/j.ejphar.2011.07.036 *
ZHANG HAO ET AL: "Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression", METABOLISM, vol. 59, no. 2, 1 February 2010 (2010-02-01), US, pages 285 - 292, XP093189125, ISSN: 0026-0495, DOI: 10.1016/j.metabol.2009.07.029 *

Also Published As

Publication number Publication date
EP4232045A1 (fr) 2023-08-30
WO2022083713A1 (fr) 2022-04-28
CN116782898A (zh) 2023-09-19

Similar Documents

Publication Publication Date Title
EP4232045A4 (fr) Compositions de berbérine ursodésoxycholate et méthodes associées pour le traitement de stéatose hépatique, de diabète et d'hyperlipidémie
MY187988A (en) Composition for treating hyperlipidemia comprising oxyntomodulin derivative
PH12015502136A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
IL288375A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
IL285989A (en) A method for treating fatty liver disease and/or fatty liver inflammation
ZA202306105B (en) Heart-nourishing and nerve-soothing pharmaceutical composition and method for preparation thereof and application thereof
EP4171566A4 (fr) Composés de liaison au céréblon, compositions de ceux-ci et procédés de traitement avec ceux-ci
IL282251A (en) Compositions and methods for treatment of liver disease
ZA202205289B (en) Compositions and methods for treating liver disease
EP4171568A4 (fr) Composés de liaison au céréblon, compositions de ceux-ci et procédés de traitement avec ceux-ci
EP3933030A4 (fr) Composition pour la prévention, le soulagement ou le traitement de l'obésité ou d'une stéatose hépathique, comprenant weissella hellenica wiki0103
IL311256A (en) Methods and uses of microbiome compositions, components or metabolites for the treatment of neurodegenerative diseases
EP4034109A4 (fr) Méthode et composition pour le traitement d'une maladie
EP4243855A4 (fr) Compositions et méthodes de traitement de la maladie de pompe
BR112016018077A8 (pt) inibidor de proteína de transferência de éster colesterílico (composto a), composições farmacêuticas compreendendo o mesmo, método para preparação das referidas composições e uso do composto a
EP3903806A4 (fr) Composition pharmaceutique pour le traitement de maladies médiées par l'activité trpv1
SG11202109180RA (en) Compositions and methods for treating huntington's disease
IL285751A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
ZA202107235B (en) Compositions and methods for treating ocular disease
EP4154880A4 (fr) Composition pharmaceutique destinée au traitement des stéatoses hépatiques
EP3976053A4 (fr) Compositions et méthodes de traitement d'une maladie métabolique
EP4017484A4 (fr) Composition d'acide gras mono-insaturé et son utilisation pour le traitement d'une stéatose hépatique
EP3999077A4 (fr) Composition et méthode de traitement du diabète
GB201907547D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B
EP4247415A4 (fr) Composition pharmaceutique pour le traitement de maladies du foie à utilisant la ssu72

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230517

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240806

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/48 20060101ALI20240731BHEP

Ipc: A61K 9/20 20060101ALI20240731BHEP

Ipc: A61P 3/10 20060101ALI20240731BHEP

Ipc: A61P 3/06 20060101ALI20240731BHEP

Ipc: A61P 1/16 20060101ALI20240731BHEP

Ipc: A61K 31/4375 20060101ALI20240731BHEP

Ipc: A61K 31/575 20060101AFI20240731BHEP